Multiple rodent models of PCOS, capitalizing mainly on the impact of androgen excess at different developmental windows, with variable penetrance in terms of reproductive and metabolic impairment, have been used in translational studies, in order to capture the phenotypic heterogeneity of the syndrome 38
Adolescent-onset Krabbe disease with an initial diagnosis of multiple sclerosis and a novel mutation
The three GLP-1 medications approved by the FDA to treat obesity include: Liraglutide (Saxenda/Victoza) Semaglutide (Wegovy/Ozempic/Rybelsus) Tirzepatide (Zepbound/Mounjaro) GLP-1 medications can lead to an average weight loss of 10% to 20% over 12-24 months when used alongside healthy diet and exercise changes
Multiple roles for mammalian target of rapamycin signaling in both glutamatergic and GABAergic synaptic transmission
Prevalence of GLP-1 or GLP-1/GIP medication use Overall, 4.5% of participants reported using a GLP-1 or GLP-1/GIP medication in the past year for any reason
Because they significantly reduce appetite, several GLP-1 medications are now FDA-approved for chronic weight management in adults with obesity or overweight with related health conditions
